Commerce Bank Purchases New Stake in IQVIA Holdings Inc. $IQV

Commerce Bank acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 38,983 shares of the medical research company’s stock, valued at approximately $7,532,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC grew its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of IQVIA during the second quarter worth approximately $514,000. First Trust Advisors LP lifted its holdings in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares during the period. 89.62% of the stock is owned by institutional investors.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This represents a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Performance

Shares of IQV opened at $260.17 on Monday. The firm has a market cap of $42.82 billion, a P/E ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $260.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The firm’s 50 day moving average price is $213.32 and its two-hundred day moving average price is $187.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the firm earned $2.81 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of analysts have commented on the stock. HSBC reaffirmed a “buy” rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. William Blair raised IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research note on Thursday, July 9th. Royal Bank Of Canada upped their price objective on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.